Baird Capital, the direct private investment arm of Robert W. Baird & Co., announced the final close of its fourth venture capital fund at $185m.
Exceeding its initial target of $150m, Fund IV was oversubscribed, with support from several institutions, foundations and family offices.
Led by Gordon Pan, Michael Liang, Jim Pavlik, Benedict Rocchio and Nicole Walker, David Gregorka, Don Layden and Fred Robertson, Baird Capital partners with entrepreneurs to build high-growth companies within the technology-enabled services and healthcare sectors.
It makes venture capital, growth equity and private equity investments amounting $10m to $15m.
To date Fund IV has already invested in five companies: Catalyze, emids, Integrated Diagnostics, NeuMoDx Molecular, and WordStream.